

Marco M E Vogel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8590176/publications.pdf>

Version: 2024-02-01

21
papers

420
citations

933264

10
h-index

794469

19
g-index

24
all docs

24
docs citations

24
times ranked

878
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus disease 2019 and radiation oncologyâ€”survey on the impact of the severe acute respiratory syndrome coronavirus 2 pandemic on health care professionals in radiation oncology. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 346-353.	1.0	2
2	PSMA-PET/CTâ€”based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. <i>European Urology Oncology</i> , 2021, 4, 73-83.	2.6	30
3	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€”detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	1.6	34
4	Web-Based Patient Self-Reported Outcome After Radiotherapy in Adolescents and Young Adults With Cancer: Survey on Acceptance of Digital Tools. <i>JMIR MHealth and UHealth</i> , 2021, 9, e19727.	1.8	4
5	Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. <i>Scientific Reports</i> , 2021, 11, 7624.	1.6	5
6	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	1.3	11
7	A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 82.	1.2	0
8	Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival. <i>BMC Cancer</i> , 2021, 21, 780.	1.1	6
9	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 715020.	1.3	9
10	Patterns of care for prostate cancer radiotherapyâ€”results from a survey among German-speaking radiation oncologists. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 962-970.	1.0	4
11	Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases. <i>BMC Cancer</i> , 2020, 20, 536.	1.1	13
12	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	3.3	13
13	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	1.1	20
14	Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. <i>Radiation Oncology</i> , 2019, 14, 198.	1.2	6
15	Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 131-144.	1.0	4
16	Cancer clinical trials â€” Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 44-49.	0.9	6
17	Mobile App Delivery of the EORTC QLQ-C30 Questionnaire to Assess Health-Related Quality of Life in Oncological Patients: Usability Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e45.	1.8	19
18	Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 192-199.	1.0	26

#	ARTICLE	IF	CITATIONS
19	mHealth and Application Technology Supporting Clinical Trials: Today's Limitations and Future Perspective of smartRCTs. <i>Frontiers in Oncology</i> , 2017, 7, 37.	1.3	16
20	Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. <i>JMIR MHealth and UHealth</i> , 2017, 5, e81.	1.8	109
21	Mobile Apps in Oncology: A Survey on Health Care Professionals' Attitude Toward Telemedicine, mHealth, and Oncological Apps. <i>Journal of Medical Internet Research</i> , 2016, 18, e312.	2.1	83